Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin - Impel Pharmaceuticals

Next Previous
Drug Profile

Insulin - Impel Pharmaceuticals

Alternative Names: INP-102; POD™ insulin

Latest Information Update: 27 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Impel NeuroPharma
  • Developer Impel Pharmaceuticals
  • Class Antidementias; Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 25 Apr 2022 Impel Neuropharma is now called Impel Pharmaceuticals
  • 14 Oct 2021 Discontinued - Phase-III for Alzheimer's disease in USA (Intranasal) (Impel NeuroPharma pipeline, October 2021).
  • 06 Sep 2018 Phase III development is ongoing for Alzheimer's disease in USA (Impel Neuropharma Pipeline - September 2018)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top